Wnt/β-Catenin Pathway in Experimental Model of Fibromyalgia: Role of Hidrox®.
Ramona D'amicoMarika CordaroRosalba SiracusaDaniela ImpellizzeriAngela Trovato SalinaroMaria ScutoMaria Laura OntarioRoberto CreaSalvatore CuzzocreaRosanna Di PaolaRoberta FuscoVittorio CalabresePublished in: Biomedicines (2021)
Fibromyalgia (FM) is a chronic condition characterized by persistent widespread pain that negatively affects the quality of life of patients. The WNT/β-catenin signaling pathway seems to be involved in central sensitization and different pain states. The objective of this study was to investigate the beneficial effects of a new compound called Hidrox® (HD), containing 40-50% hydroxytyrosol, in counteracting the pain associated with FM. An FM-like model was induced in rats by subcutaneous injections of reserpine (1 mg/kg) for three consecutive days. Later, HD (10 mg/kg) was administered orally to the animals for seven days. Reserpine injections induced WNT/β-catenin pathway activation, release of pro-inflammatory mediators as well as a significant increase in oxidative stress. Daily treatment with HD was able to modulate the WNT/β-catenin and Nrf2 pathways and consequently attenuate the behavioral deficits and microglia activation induced by reserpine injection. These results indicate that nutritional consumption of HD can be considered as a new therapeutic approach for human FM.
Keyphrases
- cell proliferation
- chronic pain
- oxidative stress
- diabetic rats
- neuropathic pain
- stem cells
- pain management
- high glucose
- endothelial cells
- ultrasound guided
- end stage renal disease
- drug induced
- ejection fraction
- newly diagnosed
- traumatic brain injury
- inflammatory response
- prognostic factors
- ischemia reperfusion injury
- peritoneal dialysis
- spinal cord injury
- patient reported outcomes
- smoking cessation
- heat stress
- stress induced